1-2 of 2
Catrine Schulz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

Free
John BAG Haanen, Andreas Mackensen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Daniel Heudobler, Peter Borchmann, Carsten Bokemeyer, Sebastian Klobuch, Alexander Desuki, Florian Lüke, Erol Wiegert, Catrine Schulz, Benjamin Rengstl, Liane Preussner, Özlem Türeci, Ugur Sahin
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT002.
https://doi.org/10.1158/1538-7445.AM2022-CT002
Published: 15 June 2022
View articletitled, Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
Journal Articles

Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma

Available to Purchase
Anja Groß, Catrine Schulz, Jasmine Kolb, Jan Koster, Sibylle Wehner, Sebastian Czaplinski, Abdulghani Khilan, Hermann Rohrer, Patrick N. Harter, Thomas Klingebiel, Julian D. Langer, Dirk Geerts, Dorothea Schulte
Journal: Cancer Research
Cancer Res (2018) 78 (8): 1935–1947.
https://doi.org/10.1158/0008-5472.CAN-17-1860
Published: 12 April 2018
View articletitled, Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma
Open the PDF for Tumorigenic and Antiproliferative Properties of the TALE-Transcription Factors MEIS2D and MEIS2A in Neuroblastoma in another window
Includes: Supplementary data